Patent · US Active

Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators

US10233173B2 · kind B2 · utility

13Cited by

5References

20Claims

0Family size

Assignee

Janssen Pharmaceuticals, Inc. · BE

Inventors

Gang Chen · Sammamish, US
Christa C. Chrovian · Village of La Jolla, US
Heather R. Coate · San Diego, US
Curt A. Dvorak · Poway, US
Christine F. Gelin · San Diego, US
Afton Hiscox · Toronto, CA
Michael A. Letavic · San Diego, US
Jason C. Rech · San Diego, US
Akinola Soyode-Johnson · San Diego, US
Brice M. Stenne · Village of La Jolla, US
Jessica L. Wall · San Diego, US
Wei Zhang · San Diego, US

Key dates

Filing date	Jul 26, 2018
Grant date	Mar 19, 2019
Priority date	—
Expiry date	Jul 26, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D417/12
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Substituted 1,2,3-triazoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.